DeepMed Research

ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

Phase 3

Completed

Conditions: HIV-1 Infection
AIDS

Interventions: Drug: Placebo
Drug: Maraviroc (Celsentri)

First Posted Date: 2011-05-05

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 407

Registration Number: NCT01348308

Locations: 🇫🇷
Hôpital Henri Mondor, Creteil, France

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin

Phase 2

Completed

Conditions: HCV Coinfection
HIV-1 Infection

Interventions: Drug: Boceprevir, Peg-interferon alfa 2b and Ribavirin

First Posted Date: 2011-04-14

Last Posted Date: 2014-10-13

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 69

Registration Number: NCT01335529

Locations: 🇫🇷
CHU Sainte Marguerite, Marseille, France

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Phase 2

Completed

Conditions: HIV Infection
Hepatitis C, Chronic

Interventions: Drug: Telaprevir
Biological: pegIFN alfa-2a
Drug: Ribavirin

First Posted Date: 2011-04-11

Last Posted Date: 2014-01-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 70

Registration Number: NCT01332955

Locations: 🇫🇷
Service Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Lyon, France

Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)

Not Applicable

Completed

Conditions: HIV
Pediatrics
Tuberculosis

First Posted Date: 2011-04-08

Last Posted Date: 2015-08-05

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 441

Registration Number: NCT01331811

Locations: 🇧🇫
CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso
🇰🇭
National Pediatric Hospital, Phnom Penh, Cambodia
🇨🇲
Centre Hospitalier d'Essos, Yaounde, Cameroon

and more 5 locations

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Phase 3

Withdrawn

Conditions: HIV

Interventions: Drug: Lopinavir
Drug: Atazanavir

First Posted Date: 2010-12-07

Last Posted Date: 2012-11-08

Lead Sponsor: ANRS, Emerging Infectious Diseases

Registration Number: NCT01255371

Locations: 🇹🇿
NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital, Mbeya, Tanzania
🇿🇦
Tshepang clinic, Limpopo University, Pretoria, South Africa

Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study

Not Applicable

Completed

Conditions: Hiv Infection
Lung Cancer

Interventions: Radiation: Low dose computed tomography (CT)

First Posted Date: 2010-09-23

Last Posted Date: 2015-07-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 450

Registration Number: NCT01207986

Locations: 🇫🇷
Makinson, Montpellier, France

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

Phase 3

Conditions: Chronic Hepatitis B
AgHbs Negativation

Interventions: Drug: Pegylated interferon-alpha-2a
Drug: Nucleotidic or Nucleosidic Treatment

First Posted Date: 2010-07-29

Last Posted Date: 2013-03-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 185

Registration Number: NCT01172392

Locations: 🇫🇷
Hôpital Saint Joseph, Service d'hépatogastroentérologie, Marseille, France

Cohort of HIV Associated Lymphomas

Completed

Conditions: HIV Infection

First Posted Date: 2010-07-16

Last Posted Date: 2017-11-06

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 205

Registration Number: NCT01164436

Locations: 🇫🇷
BESSON, Paris, France

Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: AZT-3TC-LPV/r twice a day
Drug: ABC-3TC-EFV once a day

First Posted Date: 2010-05-20

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 161

Registration Number: NCT01127204

Locations: 🇧🇫
Service de pédiatrie - CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso
🇨🇮
CEPREF, Abidjan, Côte D'Ivoire
🇨🇮
FSU abobo-Avocatier, Abidjan, Côte D'Ivoire

and more 1 locations

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
Drug: darunavir/ritonavir QD + raltegravir BID

First Posted Date: 2010-02-10

Last Posted Date: 2013-11-06

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 800

Registration Number: NCT01066962

Locations: 🇮🇹
Torvergata University, Rome, Italy
🇪🇸
Hospital Clinic, Barcelona, Spain
🇮🇹
University of Brescia, Brescia, Italy

and more 74 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy